Do CCR5 Antagonists Improve the Overall Survival of Patients With AIDS-related Progressive Multifocal Leucoencephalopathy?

Completed

• Conditions: Progressive Multifocal Leucoencephalopathy (PML); AIDS

• Registration Number: NCT03969550
• Lead Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Brief Summary

Progressive multifocal leucoencephalopathy (PML) is a demyelinating disease caused by John Cunningham virus (JCV) reactivation. Numerous molecules have been overstated because there were inaccurately tested in non-rigorous clinical trial.

The objective is to draw lessons from repeatedly false hopes of unconfirmed PML treatments that might contribute to prescribing ineffective drugs on claimed efficacy in case reports or small series and by failing to respect the need for clinical trial evaluation before authorizing their widespread use.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-01
• Primary Completion: 2015-12
• Study Completion: 2015-12
• Status Verified: 2019-05
• Study First Submitted: 2019-05-29
• Study First Submitted QC: 2019-05-29
• Last Update Submitted: 2019-05-29
• Study First Posted: 2019-05-31
• Last Update Posted: 2019-05-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• Patients with AR-PML
• Diagnosed between January 2008 and December 2015
• Followed in one of the four University Hospitals' Infectious Diseases Departments

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival (OS)	8 years